Alterity Therapeutics
Alterity Therapeutics Limited focuses on developing therapies to treat neurodegenerative diseases associated with aging, like Alzheimer's and Parkinson's disease. The company leverages a novel drug development platform aimed at targeting misfolded proteins. Positioned as a pioneer in this field, Alterity aims to address significant unmet needs in the neurosciences market.
Short position
Alterity Therapeutics (ASX:ATH) has 0.02% of its shares on issue reported as short positions as of 5 Oct 2026, or about 45,003 shares. Over the past 30 days that figure has fallen 0.09 percentage points, and over 90 days it has been broadly flat. Its highest recorded short interest was 1.18% in January 2024. ATH is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4Alterity Therapeutics (ATH) short interest history
ATH Short Interest History
- 30-day change
- -0.09pp
- 90-day change
- +0.02pp
- 1-year change
- -0.14pp
- All-time high
- 1.18% (January 2024)
- All-time low
- 0.00% (November 2021)
Is ATH heavily shorted?
Not especially: 0.02% short interest is modest by ASX standards, ranking #555 of 799 ASX securities with reported short positions. ASIC requires positions of 0.01% of issued capital or $100,000 (whichever is less) to be reported.
How has ATH's short interest changed recently?
Over the past 30 days Alterity Therapeutics's short interest has been broadly stable, and over 90 days it has been broadly stable. The current level is 0.02% of shares on issue.
What is the highest ATH's short interest has been?
Since 2020, Alterity Therapeutics's short interest peaked at 1.18% in January 2024 and bottomed at 0.00% in November 2021.
Where does this data come from?
All figures are sourced from daily ASIC short position reports, published with a four trading-day (T+4) delay. Shorted aggregates the full history since 2020. See our methodology.